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Introduction
Prolong hypophosphatemia may result in future bone loss which will have effect on patient’s quality of life. Hypophosphatemia
is observed in 431% of HIV-infected patients receiving highly active antiretroviral therapy (HAART). Fibroblast growth factor
23 (FGF-23), a potent phosphaturic hormone, has not been well studied in HIV-infected Thai patients. We aimed to investigate
whether FGF-23 is involved in the etiology of hypophosphatemia in our HIV-positive patients on HAART.
Method
This study was a case-controlled study at HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand during June
2011-May 2012. Serum and urine phosphate was studied in 696 well-suppressed HIV-infected patients. Hypophosphatemia was
defined as a serum phosphate level B2.5 mg/dl. All fasting blood and urine samples were taken between 7.00 and 10.00 hr to
measure serum phosphate, calcium, 1,25 OHD, parathyroid hormone (PTH), FGF-23 and urinary phosphate excretion. The renal
phosphate threshold tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR) was calculated. eGFR
was calculated using the MDRD.
Results
Totally 65 (9.3%) subjects were identified for hypophosphatemia. The prevalence of hypophosphatemia was not difference
between TDF exposure [(46/544: 8.5%) and TDF unexposure (19/154: 12.5%), p0.13]. However, only 56 subjects for a case
group (hypophosphatemia group) and 65 subjects with normal phosphate (normophosphatemia group were included in this
analysis. In the hypophosphatemia group, they were more likely younger, less female, and lower CD4 cell counts than the control
group. About 80% and 74% of the case and control group had TDF exposure, respectively. The renal phosphate reabsorption
threshold was significantly lower in hypophosphatemia group than in the control [43 (2.192.6) vs 3.16 (2.923.61) mg/dl,
pB0.001]. FGF-23 was significantly higher in hypophosphatemia group [31.9 (24.740.0) vs 26.2 (19.334.1) pg/dl, pB0.017].
TmP/GFR was strongly related to FGF-23 levels (pB0.04), but not for PTH (pB0.06), and urine calcium (pB0.07).
Conclusion
FGF-23 is involved in pathogenesis of hypophosphatemia in our HIV-positive patients on HAART.
Published 11 November 2012
Copyright: – 2012 Avihingsanon A et al; licensee International AIDS Society. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection
Avihingsanon A et al. Journal of the International AIDS Society 2012, 15(Suppl 4):18311
http://www.jiasociety.org/index.php/jias/article/view/18311 | http://dx.doi.org/10.7448/IAS.15.6.18311
1